title: In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: no.
authors.affiliation: Department of Clinical Neuroscience, Karolinska Institutet and University Hospital, Stockholm, Sweden. jan.hillert@ki.se
authors.forename: Jan
authors.initials: J
authors.lastname: Hillert
mesh_terms: D000284:Administration, Oral; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects*; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab; D010455:Peptides; D000068717:Glatiramer Acetate; D007372:Interferons